Trends of etiology and treatment in hepatocellular carcinoma over the years

Background: HCC has been the fastest-growing cause of cancer-related deaths. The aim of this study was to investigate the change trends in the etiology, treatment and mortality of HCC over the last 12 years.Methods: The study included 523 patients who were admitted to our clinic with the diagnosis of primary malignancy of the liver between 2006-2018. Demographic data, HCC etiologies, alpha feto-protein (AFP) values and imaging characteristics were recorded. The patients were divided into two groups as diagnosed before 2013 and 2013 and later. Because the number of patients with alcohol and HBV was high, it was evaluated as a separate etiology group. HCC was accepted related to NASH in the patients with obesity and diabetes mellitus (DM) after exclusion of HBV, HCV, and autoimmune hepatitis. The patients without obesity and DM were accepted as cryptogenic HCC and added to other etiologies group.Results: When the patients were evaluated, there was a significant increase in the rate of patients who were in compensated cirrhosis stage and in UCSF criteria in and 2013 and later (p = 0.0001, p = 0.037, respectively). A significant increase was observed in the ratio of NASH-related HCC 2013 and later (p = 0.032). Transplantation, resection and RFA / PEI rates were 14.9% before 2013 and 22.2% 2013 and later (p = 0.047).Conclusions: The rates of NAFLD related HCC due to diabetes and obesity are increasing. Knowing the change of HCC causes over the years is necessary for the effective treatment for these reasons in the future

An Evaluation of the Correlation between Hepcidin Serum Levels and Disease Activity in Inflammatory Bowel Disease

Aim. While there are many well-defined serological markers for inflammatory bowel disease (IBD), there is limited evidence that they positively affect clinical outcomes. This study aimed to evaluate the correlation between hepcidin serum levels and disease activity in IBD. Materials and Methods. Eighty-five consecutive IBD patients were enrolled in the study. Hepcidin serum levels were assessed using an enzyme-linked immunosorbent assay (ELISA) and were compared with disease activity as well as the interleukin-6 (IL-6) and C-reactive protein (CRP) levels. Results. The mean hepcidin serum levels in Crohn’s disease (CD) patients in remission and in the active phase were 3837±1436 and 3752±1274 pg/mL, respectively P=0.613. The mean hepcidin serum levels in ulcerative colitis (UC) patients in remission and in the active phase were 4285±8623 and 3727±1176 pg/mL, respectively P=0.241. Correlation analysis between inflammatory markers and hepcidin serum levels indicated that there was no correlation between hepcidin levels and IL-6 P=0.582 or CRP P=0.783. Conclusion. As an acute-phase protein, hepcidin seems to have a lower efficacy than other parameters in the detection of activation in IBD

Livedoid Vasculopathy with Behcet Disease

Livedoid vasculopathy is a rarely encountered disease. A 15-year-old girl presented with painful ulcerations, porcelain-white atrophic scars of the malleolar region and dorsal aspect of the feet, livedo reticularis on the limbs. Arthralgia was an accompanying complaint and she was overwhelmed by oral ulcers and folliculitis. Also she had family history for Behcet disease. By analyzing the case mentioned above, a rarely encountered vasculitis form of Behcet disease has been emphasized

An Evaluation of the Correlation between Hepcidin Serum Levels and Disease Activity in Inflammatory Bowel Disease

Aim. While there are many well-defined serological markers for inflammatory bowel disease (IBD), there is limited evidence that they positively affect clinical outcomes. This study aimed to evaluate the correlation between hepcidin serum levels and disease activity in IBD. Materials and Methods. Eighty-five consecutive IBD patients were enrolled in the study. Hepcidin serum levels were assessed using an enzyme-linked immunosorbent assay (ELISA) and were compared with disease activity as well as the interleukin-6 (IL-6) and C-reactive protein (CRP) levels. Results. The mean hepcidin serum levels in Crohn's disease (CD) patients in remission and in the active phase were 3837 ± 1436 and 3752 ± 1274 pg/mL, respectively ( = 0.613). The mean hepcidin serum levels in ulcerative colitis (UC) patients in remission and in the active phase were 4285 ± 8623 and 3727 ± 1176 pg/mL, respectively ( = 0.241). Correlation analysis between inflammatory markers and hepcidin serum levels indicated that there was no correlation between hepcidin levels and IL-6 ( = 0.582) or CRP ( = 0.783). Conclusion. As an acute-phase protein, hepcidin seems to have a lower efficacy than other parameters in the detection of activation in IBD